The stock's fall snapped a two-day winning streak.

EST Ocugen (OCGN) files to sell 57.54M shares of common stock for holdersInvest with Confidence: Follow TipRanks' Top Wall Street ...

This was the stock's second consecutive day of gains.

Biopharmaceutical company Ocugen, Inc. (NASDAQ: OCGN) has announced that the U.S. Food and Drug Administration (FDA) has ...

Ocugen Inc (OCGN) stock saw a decline, ending the day at $0.73 which represents a decrease of $-0.05 or -6.41% from the prior close of $0.78. The stock opened at $0.78 and touched a low of $0.71 ...

Ocugen (OCGN) announced that the U.S. FDA has reviewed the company’s Investigational New Drug application and it is in effect. This is a ...

On Friday, Ocugen Inc (OCGN) stock saw a modest uptick, ending the day at $0.78 which represents no change from the prior close of of $0.78. The stock opened at $0.79 and touched a low of $0.77 during ...

As the percentage of the global population over 65 continues to increase, the popularity of anti-aging stocks is rising in ...

“We are enthusiastic about getting patients started in the OCU200 Phase 1 clinical trial and sharing not only safety but preliminary efficacy data as the study progresses,” said Dr. Huma Qamar, Chief ...

Jan. 27, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies ...

At close: 14 November at 4:00 pm GMT-5 ...

MALVERN, Pa., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering ...